Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUL semaglutide cardiovascular outcomes trial
NL-OMON55698Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide with Placebo (2 arms). Started Aug 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON55698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55698.